Exceptional cancer care, close to home.

Transcription

1 Exceptional care, close home Annual Reptg Outcomes 1

2 Permance Measures Surgery not first treatment certa lung s Measure: Surgery not first treatment course cn2, M0 lung cases outcomes: permance rate at superi state (92.9%) national (91.4%) permance rates when compared with programs. 92.9% 89.9% 91.4% 92.9% 89.9% 91.4% Systemic Chemapy certa lung s () Measure: Systemic chemapy with 4 admtered months day preoperatively day surgery 6Samaritans months posperatively,.lymph lung United Medical Center Presence St. Mary s Hospital regional nodes colons 15 lymph nodes it considered surgically resected cases with clude surgery not beg s first course program by American College by American College Surgeons gastric. lung lymph node-positive (pn1) NSCLC treatment surgery certa not lungbeg s Surgeons (ACoS) Commsion on (). (ACoS) Commsion on (). (pn2) clude first systemic course chemapy considered admtered Commsion partnered withfum, 83.3% partners with has American treatment certa lung s chemapy outcomes: permance rate at lymph lymph node Fum (NQF), American Society Clical Society Clical Oncology, node positive positivelung lung.. superi state () national () Oncology (ASCO) Comprehensive Comprehensive Netwk provide rectal preoperative permance rates when compared with followg are most current estimated Netwk (NCCN) provide programs. programs with permance posperative chemapy radiation certa permance repted 2015 cases programs with permance s s comparon on an annual bas as staged rectal rates s. diagnosed between based on 1 on an annual basse as a method evidence acomparon method assess care. Practice Prile Rept (CP3R)2. followg are most current estimated se evidence based, assess care.1will based s be used national estimated permance rates shown dicate permance rates repted 2017below cases rigously developed s will be accountability programs dedicated improvg 83.3% proption breast, colon, lung cervical patients diagnosed 2015 based on used national accountability care haveprograms maximaldedicated beneficial treated accdg recognized care by Practice Prile Rept (C3PR)2.stards estimated improvg care have impact on outcomes population. diagnos year.rates graphs reflect proption most permance shown below dicate maximal beneficial impact onbreast outcomes Accountability s clude current provided by population. Accountability breast breast, colon, lung, rectal patients treated rapy s recepr cluded rapy accdg recognized stards care by diagnos positive tums, chemapy Data compares Presence United Samaritans recepr positive tums, chemapy year. graphs reflect most Medical current negative, radiation after mastecmy if Center ( on chart) hospitals negativelymph,nodes, radiation followg provided by four me positive radiation, East/Nth/Central regions, all ACoS lumpecmy. Surveillance cervical followg lumpecmy. accountability -approved programs Hospital all teachg Data compares Presence St. Mary s (PSMH complete radiation rapy with 60 colon cludes chemapy hospital programs United States. on chart) hospitals all ACoS days itiation women with any stage cervical Stage III colon. charts show that our Center outcomes exceed -approved programs. charts show that. Colectal cludes breastaccountability cludes a needle comparative sources many permance 78% Presence St. Mary s Hospital s 76.5% excels chemapy. palpation guided biopsy colon diagnos. Removal s compared s. all sites. 1. Desch CE, McNiff KK, Schneider D, McClure E, et American Society many Clical Oncology/ Comprehensive Netwk Measures. permance examation 12 EC, Schrag me lymphj, Lep nodes al.colon J Cl Onc, 2008: 26(21), colon gastric s was recommended as aon 2. American College Surgeons-Commsion (ACoS-) September 2013 cludes removal examation at least 12 Data Base (NCDB) Practice Prile Rept (CP3R)

3 Permance Measures Perman Breast Needle Biopsy () Establh Diagnos Radiation rapy Followg Mastecmy Pri Surgical Surgery Intervention not first treatment Breast () certa Measure: lung Image s Surgery not first treatment palpation-guided needle Measure: Radiation rapy considered biopsy (ce FNA primary site) permed admtered certa lung followg s Measure: Surgery not first treatment any mastecmy with 1 year establh course diagnos cn2, M0 breast lung cases (365 days) Measure: diagnos Surgery breast not first treatment women with > = 4 positive regional lymph nodes PSMH Outcomes: PSMH permance rate at 97.6% course cn2, M0 lung cases outcomes: permance rate at superi superi state state (91.8%) (92.9%) national national () (91.4%) PSMH Outcomes: outcomes: PSMH permance rate rate at permance rates rates when when compared compared with with superi state (90.7%) (92.9%) national (86.2%) (91.4%) programs. programs. permance rates when compared with programs. 97.6% 89.9% 91.8% 92.9% 91.4% 92.9% 90.7% 91.4% 86.2% PSMH 89.9% Systemic Chemapy certa lung Breast s Conservg () Surgery/Radiation rapy F Breast (BCS/RT) Measure: Systemic chemapy BCS/RT Measure: Radiation admtered with 4 months rapy day admtered preoperatively with 1 year (365 days) diagnos day surgery 6 months posperatively, women under it age considered 70 receivg surgically breast conservg resected cases surgery with (lumpecmy) lymph vasive node-positive breast. (pn1) One (pn2) year NSCLC identified as a Surgery not allow first medical treatment tervention followg certa surgery. lung outcomes: s permance rate at Most ten radiation 83.3% rapy superi state () national () delivered with one six months surgery. Radiation permance Measure: rates Surgery when compared not first with treatment treatment course should start as soon as medically feasible. cn2, M0 lung programs. cases PSMH Outcomes: outcomes: PSMH permance rate rate 90% at slightly superi lower than state state (92.9%) (93.1%) national national (91.4%) (90.2%) permance rates when compared 89.9% with programs. 83.3% Permance Measures 90% 92.9% 93.1% 91.4% 90% PSMH 89.9% PSMH Perman Systemic Chemapy certa lung Hmone s rapy () (HT) F Hmone Recepr Positive Breast Measure: Surgery Systemic HT Measure: Hmone not chemapy first treatment admtered with 4 months rapy considered day preoperatively admtered certa lung with s day surgery 1 6 year months (365 posperatively, days) diagnos women it considered with Measure: AJCC T1cN0M0, surgically Surgery resected not Stage first II cases treatment III with recepr course positive cn2, lymph M0 breast node-positive lung. cases (pn1) (pn2) NSCLC PSMH Outcomes: outcomes: PSMH permance rate rate 94.7% at superi state (93.6%) () (92.9%) national (91.2%) (91.4%) () permance rates when compared with programs. Systemic 1. Desch CE, McNiff Chemapy KK, Schneider EC, Schrag 76.5% D, McClure certa J, Lep 78% E, lung et al. American Society Clical Oncology/ Comprehensive Netwk Measures. J Cl Onc, 2008: 26(21), Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lep E, et al. American Society C s 2. American College () Surgeons-Commsion on (ACoS-) Data Base (NCDB) Practice Prile Rept (CP3R) September 2013 Measure: Systemic chemapy 2. American College Surgeons-Commsion on (ACoS-) Data Bas admtered with 4 months day preoperatively 94.7% 92.9% 93.6% 91.4% 91.2% PSMH Systemic Chemapy certa lung s () Measure: Systemic chemapy admtered with 4 months day preoperatively J Cl day Onc, 2008: surgery 26(21), months posperatively, it considered surgically resected cases with 3 lymph node-positive (pn1) (pn2) NSCLC

4 Permance Measures Perman Permance Measures Multi-Agent Chemapy (MAC) Treatment F Hmone Recepr Surgery Negative not first Breast treatment MAC certa Measure: lung Surgery Multi-agent s not chemapy first treatment considered certa admtered lung Measure: with s 4 Surgery months (120 not first days) treatment diagnos women under 70 with AJCC T1cN0M0, Stage II III course recepr Measure: cn2, M0 negative Surgery lung cases breast not. first treatment course outcomes: cn2, M0 lung casespermance rate at PSMH superi Outcomes: PSMH state permance (92.9%) national rate outcomes: (91.4%) superi permance rates state when (92.9%) permance rate at compared national with (92.6%) superi state (92.9%) national (91.4%) permance rates when programs. compared with permance rates when compared with programs. programs. 89.9% 92.6% 89.9% PSMH Systemic Chemapy 92.9% 91.4% certa lung Systemic s Chemapy () certa lung Adjuvant Chemapy s Treatment F Lymph Measure: () Systemic chemapy Node Positive Colon admtered (ACT) Measure: Systemic with 4 months chemapy day preoperatively ACT Measure: day surgery Surgery Adjuvant 6 chemapy not months first posperatively, treatment considered admtered with 4 months day preoperatively admtered certa it day considered surgery lung with s 46 surgically months (120 posperatively, resected days) cases diagnos with patients it under lymph age node-positive 80 with AJCC (pn1) Stage (pn2) III (lymph NSCLC considered Measure: surgically Surgery node positive) resected not first cases treatment with outcomes: colon. 83.3% course cn2, lymph M0 node-positive lung casespermance (pn1) (pn2) rate at NSCLC PSMH superi Outcomes: PSMH state () national rate () outcomes: permance rate at permance rates when (91.4%) () compared with (87.2%) superi state (92.9%) programs. national (91.4%) () permance rates when 89.9% compared with programs. 83.3% 91.4% 87.2% PSMH Permance Measures 89.9% 12 Regional Lymph Nodes Examed F Colon Surgery not first treatment 12RLN certa Measure: lung s At least 12 regional lymph nodes are removed Measure: ally Surgery examed not first treatment resected colon. course cn2, M0 lung cases PSMH Outcomes: outcomes: PSMH permance rate rate at superi state (93.1%) (92.9%) national (92.0%) (91.4%) permance rates when compared with programs. Systemic Chemapy certa lung s Surgery () Surgery not not first first treatment treatment certa lung certa s lung s Measure: Systemic chemapy admtered Measure: with Surgery 4 months not not day first first preoperatively treatment course course cn2, day M0 surgery lung cn2, M0 cases lung 6 months casesposperatively, PSMH it considered Outcomes: outcomes: PSMH surgically permance resected rate cases rate with at superi lymph state node-positive (91.9%) (92.9%) (pn1) national (pn2) (91.9%) (91.4%) NSCLC permance outcomes: rates when compared permance with rate at superi state programs. () national () permance rates when compared with programs. 92.9% 91.9% 91.4% 91.9% Measure: Systemic chemapy Systemic Chemapy certa lung admtered with 4 months day preoperatively s () 76.5% 78% day surgery 6 months posperatively, 1. Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lep E, et al. American Society Clical Oncology/ Comprehensive Netwk Measures. Measure: Systemic it considered surgically resected cases with 1. Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lep E, et al. American Society C chemapy J Cl Onc, 2008: 26(21), J Cl Onc, 2008: lymph 26(21), node-positive (pn1) (pn2) NSCLC admtered 1. Desch 2. American CE, McNiff College KK, with Schneider 4 Surgeons-Commsion EC, months Schrag D, McClure day on J, preoperatively Lep (ACoS-) E, et al. American Society Data Base Clical 2. (NCDB) American Oncology/ College Surgeons-Commsion Comprehensive Practice Prile Rept on Netwk (CP3R) September (ACoS-) Measures Data Bas 83.3% J Cl day Onc, 2008: surgery 26(21), months posperatively, outcomes: permance rate at 2. American College Surgeons-Commsion on (ACoS-) Data Base (NCDB) Practice Prile Rept (CP3R) September 2013 it considered surgically resected cases with superi state () national () lymph node-positive (pn1) (pn2) NSCLC permance rates when compared with 92.9% 93.1% 91.4% 92% PSMH Perman PSMH Systemic Chemapy certa lung s ()

5 Perman Permance Measures Permance Measures Systemic Chemapy certa lung s () Measure: Systemic chemapy admtered with 4 months Surgery day preoperatively not first treatment day surgery certa 6 months lung posperatively, s it considered surgically resected Measure: cases Surgery with not first treatment lymph node-positive course cn2, (pn1) M0 lung (pn2) cases NSCLC PSMH Outcomes: outcomes: PSMH permance permance rate rate 2015 at was superi N/A as no patients state fit (92.9%) th criteria national (91.4%) state was permance at 91.4% rates when national compared rate 89.9% was with 89.1%. programs. programs. 91.4% 89.1% PSMH 89.9% NO DATA Systemic Chemapy certa lung Pre-operative post-operative chemapy s () radiation rapy certa rectal s (RECRTCT) Measure: Systemic chemapy admtered with 4 months day preoperatively RECRTCT day Measure: surgery Preoperative 6 months 83.3% posperatively, chemo radiation are it admtered clical AJCC T3N0, T4N0, Stage considered III; posperative Surgery surgically not chemo first resected treatment cases with radiation are lymph node-positive (pn1) (pn2) NSCLC admtered certa lung with s 180 diagnos clical AJCC T1-T2N0 with outcomes: AJCC permance T3N0, T4N0, rate Stage at Measure: Surgery not first treatment III; treatment superi recommended; state () patients national under () course cn2, M0 lung cases age permance 80 receivg rates resection when compared rectal with outcomes: programs. permance rate at PSMH superi Outcomes: PSMH state (92.9%) permance 83.3% national rate (91.4%) 2015 was N/A permance as no patients rates fit when th criteria compared with state was at 89.1% national programs. rate was 86.7%. 15 Regional Lymph Surgery Nodes not Examed first treatment Gastric certa (G15RLN) lung s Permance Measures 92.9% 89.1% 91.4% 86.7% G15RLN Measure: Measure: At Surgery least 15 regional not first lymph treatment nodes are course removed cn2, M0 ally lung cases examed resected gastric ( Improvement) outcomes: permance rate at PSMH superi Outcomes: PSMH state (92.9%) permance national rate (91.4%) 2015 was N/A permance as no patients rates fit when th criteria compared with state was at 66.2% national programs. rate was 61.1%. PSMH NO DATA 76.5% 78% 1. Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lep E, et al. American Society C J Cl Onc, 2008: 26(21), American College Surgeons-Commsion on (ACoS-) Data Bas 1. Desch Systemic CE, McNiff KK, Chemapy Schneider EC, Schrag D, McClure certa J, Lep E, et lung al. American Society Clical Oncology/ Comprehensive Netwk Measures. J Cl s 1. Desch Onc, 2008: CE, McNiff 26(21), () KK, Schneider EC, Schrag D, McClure J, Lep E, et al. American Society Clical Oncology/ Comprehensive Netwk Measures. 2. American J Cl Onc, College 2008: 26(21), Surgeons-Commsion on (ACoS-) Data Base (NCDB) Practice Prile Rept (CP3R) September American Measure: College Systemic Surgeons-Commsion chemapy on (ACoS-) Data Base (NCDB) Practice Prile Rept (CP3R) September 2013 PSMH NO DATA Systemic Chemapy certa lung s () Measure: Systemic chemapy admtered with 4 months day preoperatively day surgery 6 months posperatively, it considered surgically resected cases with lymph node-positive (pn1) (pn2) NSCLC outcomes: permance rate at superi state () national () permance rates when compared with programs. 66.2% 61.1%

6 Presence Care Medical Oncology Radiation Oncology Highly skilled, specialized physicians with university-level experte Hemalogy, Oncology Radiation Oncology Get uch. Presence Care Rt. 45 Bourbonna, Hemalogy/Oncology Radiation Oncology Bourbonna Imagg Presence St. Mary s Hospital Dedicated suppt staff asst you your family with many challenges Oncology Certified Nurses Breast Nurse Navigars who deliver nursg care Community education programs screengs most state---art treatments available a community settg just mutes away Availability opptunity clical research trials Msion Statement Inspired by healg mtry Jesus Chrt, we Presence Health, a Catholic health system, provide compassionate, holtic care with a spirit healg hope communities we serve.